In this latest rapid-reference memory aid from Diabetes & Primary Care, Pam Brown summarises the doses, indications and licences of the SGLT2 inhibitor class of diabetes drugs in adults.
Update history
19 October 2023: Updated to reflect changes in licensing for empagliflozin.
Early data from the NHS Type 2 Diabetes Path to Remission programme show it is effective in achieving remission at scale outside of clinical trials.
3 Sep 2024